JAN 25, 2018 8:00 AM PST

WEBINAR: Understanding Immunosuppressive Myeloid Cells and Immunotherapy using Proteome Profiler™ Arrays

Sponsored by: Bio-Techne
Speaker

Abstract

DATE: January 25, 2018
TIME:  8:00AM PST, 10:00AM CST

Prostate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treated with androgen deprivation therapy experience relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC).  The PCa tumor microenvironment is comprised of a complex mixture of epithelial and stroma cell types engaged in multifaceted heterotypic interactions functioning to maintain tumor growth and immune evasion. We recently uncovered the important role played by myeloid-derived suppressor cells (MDSCs) to mediate tumor immune evasion in aggressive PCa.  Although, Immune checkpoint blockade (ICB) has elicited durable therapeutic responses across a number of cancer types, its impact of ICB on mCRPC has been disappointing.  This signals the need to combine mechanistically-distinct ICB agents and/or override immunosuppression in the tumor microenvironment. We created a novel embryonic stem cell (ESC)-based chimeric mouse model of mCRPC engineered with signature mutations to study the response to single and combination immunotherapy. Consonant with early stage clinical trials experience, anti-CTLA4 or anti-PD1 monotherapy failed to impact disease progression. Similarly, modest anti-tumor activity was observed with combination ICB as well as monotherapy with targeted agents including Cabozantinib (tyrosine kinase inhibitor), BEZ235 (PI3K/mTOR inhibitor), and Dasatinib (tyrosine kinase inhibitor). In contrast, mCRPC primary and metastatic disease showed robust responses to dual ICB treatment together with either Cabozantinib or BEZ235, but not with Dasatinib which impaired T cell infiltration in the tumor. Taken together, we demonstrated that an antibody cocktail targeting CTLA4 and PD1 was insufficient to generate effective anti-tumor response, but combination of ICB with targeted therapy that inactivates PI3K signaling displayed superior synergistic efficacy through impairing MDSCs in the tumor microenvironment.

Learning Objectives:

  • Understand the role of the myeloid-derived suppressor cells in the context of PCa immune evasion
  • Understand the therapeutic impact of dual ICB and kinase inhibitor therapy on mCRPC

 

 


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 21, 2021 5:00 PM CEST
APR 21, 2021 5:00 PM CEST
Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
JAN 25, 2018 8:00 AM PST

WEBINAR: Understanding Immunosuppressive Myeloid Cells and Immunotherapy using Proteome Profiler™ Arrays

Sponsored by: Bio-Techne

Specialty

Cancer Research

Immunology

Molecular Biology

Cancer Therapeutics

Cell Biology

Biotechnology

Cancer Diagnostics

Biomarkers

Biochemistry

Cell Culture

Clinical Research

Clinical Chemistry

Oncology

Antibodies

Molecular Diagnostics

Geography

North America57%

Europe17%

Asia13%

South America3%

Africa3%

Oceania1%

Registration Source

Website Visitors89%

WAVE Newsletter Promotion5%

Email Promotions4%

Social Media Promotions1%

Job Title

Research Scientist15%

Student15%

Scientist14%

Executive13%

Medical Laboratory Technician9%

Educator/Faculty8%

Medical Doctor/Specialist6%

Facility/Department Manager5%

Lab Management5%

Post Doc5%

Clinical Laboratory Scientist2%

Marketing/Sales1%

QC/QA1%

Chemist1%

Biologist1%

Organization

Academic Institution12%

Biotech Company9%

Clinical Laboratory8%

Hospital6%

Research Institute5%

Pharmaceutical Company4%

Medical Center3%

Medical School2%

Industrial Company2%

Government2%

Life Science Company1%

Consultant1%

Ambulatory Care1%

Contract Research Organization (Cro)1%

Other4%


Show Resources
Loading Comments...
Show Resources
Attendees
  • See more